Hu J, Zhang Y, Jiang X, Zhang H, Gao Z, Li Y, Fu R, Li L, Li J, Cui H, Gao N
What Studies Show In a Phase 2 clinical trial published in The Lancet Diabetes & Endocrinology , patients taking survodutide experienced meaningful, dose-dependent weight loss
The most common side effects include: Nausea Vomiting Diarrhea Constipation Hypoglycemia (low blood sugar levels) Headache Dizziness Injection Site Reactions Understanding these side effects is the first step toward managing them effectively
Access to approved therapies: Improving PBS access to TGA-approved obesity pharmacotherapy may reduce grey-market appeal by addressing underlying treatment access barriers
This may include evidence of weight loss, improved health conditions, and compliance with post-surgical guidelines
Badgley MA, Kremer DM, Maurer HC, et al